K. Katić, V. Matković, J. Lešin, Pavao Planinić, Goran Vujić
{"title":"905 在 BRCA 基因突变的高级别浆液性卵巢癌患者中使用 KELIM 评分预测化疗反应:一家机构的经验","authors":"K. Katić, V. Matković, J. Lešin, Pavao Planinić, Goran Vujić","doi":"10.1136/ijgc-2024-esgo.736","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517833,"journal":{"name":"Poster and E-Posters","volume":"13 17","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"905 Using chemotherapy response by KELIM score in patient with BRCA-mutated high-grade serous ovarian cancer to predict response to first line olaparib maintenance therapy: an one institution experience\",\"authors\":\"K. Katić, V. Matković, J. Lešin, Pavao Planinić, Goran Vujić\",\"doi\":\"10.1136/ijgc-2024-esgo.736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517833,\"journal\":{\"name\":\"Poster and E-Posters\",\"volume\":\"13 17\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster and E-Posters\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.736\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster and E-Posters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
905 Using chemotherapy response by KELIM score in patient with BRCA-mutated high-grade serous ovarian cancer to predict response to first line olaparib maintenance therapy: an one institution experience